Mark Fendrick, MD, discusses the role that biosimilars will play in value-based insurance design (VBID).
Transcript:
Are biosimilars going to play a big role in value-based design?
The question about whether biosimilars play a role, branded drugs play a role, generics play a role, I think all of these questions about specific interventions take us back to what makes VBID different from other types of payment insurance schemes which is this era of clinical nuance.
It has always been our view that the value of a service depends not on the service itself, but who gets it, when in the course of the disease, by whom, and where. So, whether that be a branded drug, a generic drug, a specialty drug, or a biosimilar, there is a time in the course of the sequence of care where drugs are considered very high value, and that exact same drug might be considered low-value.
So as opposed to talking about preferred branded drugs or specialty drugs or biosimilars or generics, as many people know, there are some generics that I would pay people to take. There are also some generic drugs I would not give my dog. The same holds true for biosimilars. If there is evidence to suggest that a biosimilar at this point in time is a first-line drug, then the patient should have access to that and the provider should not have problems in terms of having to send faxes or make phone calls or whatever else to use it.
But that requires not just transparency, not just consumerism, not just skin in the game. This requires clinical expertise that fortunately or unfortunately most patients just don’t have. So instead of relying on patients to shop around, and make these types of decisions, I think the onus should be on providers. They for the most part want to do what’s best for their patients. We need to have their compensation systems aligned with good choices, but more importantly if a provider decides that something is best for his patient, whether that be a biosimilar, whether it be a specially drug, whether it be a branded drug or generic, when that clinical situation says that this is the right service for that person at this right time, there should be unfettered access to that.
So, I think in the avdent of any innovation, like biosimilars or maybe more importantly, these new CAR-T therapies moving forward, we need to access not only the clinical benefits that have come to them, not only the cost for which it has incurred, but understanding that drug and that cost, the value of which depends on the clinical scenario that it might be. It might be so important that you want barriers to fall and in some patients to do it, the exact same drug may be a complete waste and in another patient another scenario. And I think that’s where VBID fits in.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.